GlassScriptPhysician profile
Mazen Alakhras
NPI 1285617803
$1,886.95
in general payments reported to CMS, 2019-2025
21 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $258 · 2021: $110 · 2022: $90.00 · 2023: $555 · 2024: $64.94 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $475 · Food and Beverage: $235 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $475.20 |
| Food and Beverage | $235.11 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $568.92 | 2023-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $223.55 | 2019-2025 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.20 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $203.99 | 2019-2024 | Airsupra, Breztri |
| Sunovion Pharmaceuticals INC. | $133.20 | 2019-2020 | |
| United Therapeutics Corporation | $116.24 | 2020-2021 | |
| Mylan Specialty L.P. | $53.51 | 2019-2020 | |
| Genzyme Corporation | $52.38 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $48.47 | 2019-2025 | Zerbaxa |
| Gilead Sciences, INC. | $39.83 | 2019 | |
| Boston Scientific Corporation | $33.52 | 2019-2020 | |
| Electromed, INC. | $27.88 | 2019 | |
| Shire North American Group INC | $26.63 | 2019 | |
| Grifols USA, LLC | $19.56 | 2019 | |
| Circassia INC. | $19.44 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18.62 | 2023 | Dupixent |
| Resmed Corp | $18.29 | 2020 | |
| Pulmonx Corporation | $16.68 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.25 | 2019 | |
| Olympus America INC. | $15.02 | 2023 | Spin Vision Scope, 4.0mm Od, 2.0mm Wc, Spiration Valve System |
| Novartis Pharmaceuticals Corporation | $13.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Alakhras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.